158 related articles for article (PubMed ID: 36304744)
1. Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling.
Balogun TA; Chukwudozie OS; Ogbodo UC; Junaid IO; Sunday OA; Ige OM; Aborode AT; Akintayo AD; Oluwarotimi EA; Oluwafemi IO; Saibu OA; Chuckwuemaka P; Omoboyowa DA; Alausa AO; Atasie NH; Ilesanmi A; Dairo G; Tiamiyu ZA; Batiha GE; Alkhuriji AF; Al-Megrin WAI; De Waard M; Sabatier JM
Front Chem; 2022; 10():964446. PubMed ID: 36304744
[TBL] [Abstract][Full Text] [Related]
2. Identification of natural compounds (proanthocyanidin and rhapontin) as high-affinity inhibitors of SARS-CoV-2 Mpro and PLpro using computational strategies.
AlAjmi MF; Azhar A; Hasan S; Alshabr AZ; Hussain A; Rehman MT
Arch Med Sci; 2024; 20(2):567-581. PubMed ID: 38757037
[TBL] [Abstract][Full Text] [Related]
3. Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2.
Ouassaf M; Belaidi S; Mogren Al Mogren M; Chtita S; Ullah Khan S; Thet Htar T
J King Saud Univ Sci; 2021 Mar; 33(2):101352. PubMed ID: 33558797
[TBL] [Abstract][Full Text] [Related]
4. Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2.
Mohammad A; Zheoat A; Oraibi A; Manaithiya A; S Almaary K; Allah Nafidi H; Bourhia M; Kilani-Jaziri S; A Bin Jardan Y
Front Mol Biosci; 2023; 10():1306179. PubMed ID: 38516396
[No Abstract] [Full Text] [Related]
5. Determination of Novel SARS-CoV-2 Inhibitors by Combination of Machine Learning and Molecular Modeling Methods.
Güner E; Özkan Ö; Yalcin-Ozkat G; Ölgen S
Med Chem; 2024; 20(2):153-231. PubMed ID: 37957860
[TBL] [Abstract][Full Text] [Related]
6. Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase
Elkaeed EB; Alsfouk BA; Ibrahim TH; Arafa RK; Elkady H; Ibrahim IM; Eissa IH; Metwaly AM
Antivir Ther; 2023 Oct; 28(5):13596535231199838. PubMed ID: 37669909
[TBL] [Abstract][Full Text] [Related]
7. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
[TBL] [Abstract][Full Text] [Related]
8. Identification of SARS-CoV-2 inhibitors from extracts of
Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K; Al-Hemaid F
Saudi J Biol Sci; 2021 Dec; 28(12):7517-7527. PubMed ID: 34512097
[No Abstract] [Full Text] [Related]
9. Antiviral activities of natural compounds and ionic liquids to inhibit the Mpro of SARS-CoV-2: a computational approach.
Palanisamy K; Rubavathy SME; Prakash M; Thilagavathi R; Hosseini-Zare MS; Selvam C
RSC Adv; 2022 Jan; 12(6):3687-3695. PubMed ID: 35425367
[TBL] [Abstract][Full Text] [Related]
10. Docking and Electronic Structure of Rutin, Myricetin, and Baicalein Targeting 3CLpro.
Farias SAS; Rocha KML; Nascimento ÉCM; de Jesus RDCC; Neres PR; Martins JBL
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894797
[TBL] [Abstract][Full Text] [Related]
11. The dolabellane diterpenes as potential inhibitors of the SARS-CoV-2 main protease: molecular insight of the inhibitory mechanism through computational studies.
Aminah NS; Abdjan MI; Wardana AP; Kristanti AN; Siswanto I; Rakhman KA; Takaya Y
RSC Adv; 2021 Dec; 11(62):39455-39466. PubMed ID: 35492446
[TBL] [Abstract][Full Text] [Related]
12. Identification of tuna protein-derived peptides as potent SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation.
Yu Z; Kan R; Ji H; Wu S; Zhao W; Shuian D; Liu J; Li J
Food Chem; 2021 Apr; 342():128366. PubMed ID: 33092925
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
Future Med Chem; 2024 Apr; ():. PubMed ID: 38618977
[No Abstract] [Full Text] [Related]
14. Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment.
Shehroz M; Zaheer T; Hussain T
Heliyon; 2020 Oct; 6(10):e05278. PubMed ID: 33083627
[TBL] [Abstract][Full Text] [Related]
15. An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease.
Zhai T; Zhang F; Haider S; Kraut D; Huang Z
Front Mol Biosci; 2021; 8():661424. PubMed ID: 34079818
[TBL] [Abstract][Full Text] [Related]
16. Virtual screening, drug-likeness analysis, and molecular docking study of potential severe acute respiratory syndrome coronavirus 2 main protease inhibitors.
Nedeljković NV; Nikolić MV; Stanković AS; Jeremić NS; Tomović DL; Bukonjić AM; Radić GP; Mijajlović MŽ
Turk J Chem; 2022; 46(1):116-146. PubMed ID: 38143877
[TBL] [Abstract][Full Text] [Related]
17. Anti-Viral Activity of Bioactive Molecules of Silymarin against COVID-19 via In Silico Studies.
Zhang C; Sui Y; Liu S; Yang M
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895950
[TBL] [Abstract][Full Text] [Related]
18. De novo generation of dual-target ligands for the treatment of SARS-CoV-2 using deep learning, virtual screening, and molecular dynamic simulations.
Humayun F; Khan F; Khan A; Alshammari A; Ji J; Farhan A; Fawad N; Alam W; Ali A; Wei DQ
J Biomol Struct Dyn; 2024 Apr; 42(6):3019-3029. PubMed ID: 37449757
[TBL] [Abstract][Full Text] [Related]
19. In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19.
Esam Z; Akhavan M; Lotfi M; Pourmand S; Bekhradnia A
Chem Zvesti; 2023; 77(2):1129-1148. PubMed ID: 36312321
[TBL] [Abstract][Full Text] [Related]
20. Affinity selection-mass spectrometry in the discovery of anti-SARS-CoV-2 compounds.
van Breemen RB; Muchiri RN
Mass Spectrom Rev; 2024; 43(1):39-46. PubMed ID: 35929396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
